SKYE vs. INCR, CRVO, RGLS, IMAB, SGMT, RPTX, MCRB, PDSB, CTMX, and IXHL
Should you be buying Skye Bioscience stock or one of its competitors? The main competitors of Skye Bioscience include InterCure (INCR), CervoMed (CRVO), Regulus Therapeutics (RGLS), I-Mab (IMAB), Sagimet Biosciences (SGMT), Repare Therapeutics (RPTX), Seres Therapeutics (MCRB), PDS Biotechnology (PDSB), CytomX Therapeutics (CTMX), and Incannex Healthcare (IXHL). These companies are all part of the "pharmaceutical preparations" industry.
InterCure (NASDAQ:INCR) and Skye Bioscience (NASDAQ:SKYE) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their community ranking, institutional ownership, media sentiment, dividends, profitability, earnings, analyst recommendations, risk and valuation.
InterCure has higher revenue and earnings than Skye Bioscience.
8.3% of InterCure shares are held by institutional investors. Comparatively, 21.1% of Skye Bioscience shares are held by institutional investors. 0.7% of Skye Bioscience shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Skye Bioscience's return on equity of 0.00% beat InterCure's return on equity.
InterCure received 2 more outperform votes than Skye Bioscience when rated by MarketBeat users.
In the previous week, Skye Bioscience had 8 more articles in the media than InterCure. MarketBeat recorded 10 mentions for Skye Bioscience and 2 mentions for InterCure. Skye Bioscience's average media sentiment score of 1.43 beat InterCure's score of -0.24 indicating that InterCure is being referred to more favorably in the media.
Skye Bioscience has a consensus target price of $22.50, indicating a potential upside of 85.19%. Given InterCure's higher possible upside, analysts clearly believe Skye Bioscience is more favorable than InterCure.
InterCure has a beta of 1.63, suggesting that its stock price is 63% more volatile than the S&P 500. Comparatively, Skye Bioscience has a beta of 1.74, suggesting that its stock price is 74% more volatile than the S&P 500.
Summary
InterCure and Skye Bioscience tied by winning 6 of the 12 factors compared between the two stocks.
Get Skye Bioscience News Delivered to You Automatically
Sign up to receive the latest news and ratings for SKYE and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SKYE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skye Bioscience Competitors List
Related Companies and Tools
